PulseAugur
EN
LIVE 06:44:12
中文(ZH) 阳光诺和：STC009注射液临床试验申请获受理

China fines Tiger, Futu, Changqiao for illegal securities operations

By PulseAugur Editorial · [1 sources] ·

China's securities regulator is proposing significant penalties for Tiger Brokers, Futu, and Changqiao. These platforms are accused of illegally operating securities brokerage, margin financing, and futures brokerage services within mainland China without proper authorization. The regulator intends to confiscate all illegal gains and impose severe fines, while also offering the companies the right to a hearing. AI

RANK_REASON Regulatory action by a national securities commission against major financial platforms. [lever_c_demoted from significant: ic=1 ai=0.1]

Read on 36氪 (36Kr) →

AI-generated summary · Google Gemini · from 1 sources. How we write summaries →

China fines Tiger, Futu, Changqiao for illegal securities operations

How we ranked this

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
Regulatory action by a national securities commission against major financial platforms. [lever_c_demoted from significant: ic=1 ai=0.1]
Source corroboration
Single-source cluster
Only one publisher covered this so far. Single-source stories can still rank when the publisher is high-authority, but they lack cross-source corroboration.
Topics
policy, other
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
Low
Off-topic or adjacent — cluster remains reachable but doesn't surface in AI-industry rankings.
Story freshness
154 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

Full methodology in our editorial standards.

COVERAGE [1]

  1. 36氪 (36Kr) TIER_1 中文(ZH) ·

    Sunshine Noah: STC009 Injection Clinical Trial Application Accepted

    36氪获悉，阳光诺和公告，近日，公司全资子公司成都诺和晟泰生物科技有限公司收到国家药品监督管理局核准签发的《受理通知书》，在研项目STC009注射液的临床试验申请获得受理。STC009注射液拟申报适应症为继发性甲状旁腺功能亢进症（SHPT）。

RELATED ENTITIES

RELATED TOPICS